Patient-level Meta-Analysis Confirms Benefits of Toujeo® Regardless of Age of Onset of Type 2 Diabetes

– Starting with or switching to Toujeo® provided comparable glycemic control with less hypoglycemia vs Lantus® in all sub-groups   –


Results from a new meta-analysis of patient-level 6-month data from the EDITION 1, 2 and 3 Phase 3 clinical trials demonstrate that in adults with type 2 diabetes, the benefits of Toujeo® (insulin glargine [rDNA origin] injection, 300 Units/mL) are not related to age at onset of diabetes. When stratified by age at onset of diabetes, the analysis shows comparable glycemic control with reduced* risk of hypoglycemic (low blood sugar) events at night and at any time of day (24 hr) in each sub-group with Toujeo® compared with Lantus® (insulin glargine [rDNA origin] injection, 100 Units/mL).

The study abstract is titled: Age of diabetes onset: Glycemic control and hypoglycemia benefit with new insulin glargine 300 U/mL in T2DM (Twigg S et al. Poster presentation 0357-PD, December 1, 2015).

* Risk reduction is statistically significant for all patient sub-groups, except for any-time (24 hr) hypoglycemic events in patients aged >50 at onset of diabetes, where the risk reduction with Toujeo is numerical. 


The lead author of this poster presentation is Prof. Stephen Twigg, Kellion Professor of Endocrinology, Sydney Medical School, Australia. 


Tuesday, December 1, 2015 (Poster presented all day; discussion 13:00–14:00) 


International Diabetes Federation 23rd World Diabetes Congress, Vancouver Convention Centre (VCC), Vancouver, Canada. Poster displayed in poster area; Discussion at Poster Terminal 1.  


To request an interview to discuss this and other Sanofi Diabetes-sponsored research with Riccardo Perfetti, Senior Medical Officer, Vice President Medical Affairs, please contact Philip McNamara, Global Diabetes Communications (Tel.: +1 908 981 5497;